A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

Inclusion Criteria: * ≥18 years of age; * Signed Informed Consent Form; * Relapsed/refractory Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia(CMML) and others myeloid neoplasm; * IDH1 and/or IDH2 mutated disease status as assessed by local laboratory; * Cooperative Oncology Group (ECOG) performance status of 0-2; * Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling, and urine sampling during the study. Exclusion Criteria: * Previously treated with any prior IDH1 inhibitor, IDH2 inhibitor, or IDH1/IDH2 double-targeted therapy and had disease progression during treatment; * with known involvement or clinical symptoms of central nervous system (CNS); * Patients who have undergone HSCT within 60 days; * Without adequate liver or kidney function; * With known infection with active hepatitis B or C; * With known infection with human immunodeficiency virus (HIV); * History of clinically significant or active cardiac disease; * Active clinically significant infection; * Taking known strong cytochrome P450 (CYP) 2C8 inducers or inhibitors; * Pregnancy or breast-feeding.